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Cost-effectiveness of a complex
intervention to reduce children’s exposure
to second-hand smoke in the home
Charlotte Renwick1, Qi Wu1* , Magdalena Opazo Breton2, Rebecca Thorley3, John Britton4, Sarah Lewis4,
Elena Ratschen1 and Steve Parrott5
Abstract
Background: Second-hand smoke (SHS) causes numerous health problems in children such as asthma, respiratory
tract infections and sudden infant death syndrome. The home is the main source of exposure to SHS for children,
particularly for young children. We estimated the cost-effectiveness of a complex intervention designed to reduce
SHS exposure of children whose primary caregiver feels unable or unwilling to quit smoking.
Methods: A cost-effectiveness analysis was carried out alongside an open-label, parallel, randomised controlled trial
in deprived communities in Nottingham, England. A complex intervention combining behavioural support, nicotine
replacement therapy and personalised feedback on home air quality was compared with usual care. A total number
of 205 households were recruited, where the main caregivers were aged 18 and over, with a child aged under five
years living in their household reporting smoking inside their home. Analyses for this study were undertaken from
the National Health Service/Personal Social Services perspective. All costs were estimated in UK pounds (£) at 2013/
14 prices. The primary outcome was the incremental cost-effectiveness of change in air quality in the home,
measured as average 16–24 h levels of particulate matter of < 2.5 μm diameter (PM2.5), between baseline and
12 weeks. Secondary outcomes included incremental cost per quitter, quit attempts and cigarette consumption in
the home. A non-parametric bootstrap re-sampling technique was employed to explore uncertainty around the
calculated incremental cost-effectiveness ratios.
Results: The complex intervention achieved reduced PM2.5 by 21.6 μg/m
3 (95% CI: 5.4 to 37.9), with an incremental
cost of £283 (95% CI: £254–£313), relative to usual care. The incremental cost-effectiveness ratio was £131
(bootstrapped 95% CI: £72–£467) per additional 10μg/m3 reduction in PM2.5, or £71 (bootstrapped 95% CI: -£57-
£309) per additional quitter.
Conclusions: This trial targeted a socio-economically disadvantaged population that has been neglected within the
literature. The complex intervention was more costly but more effective in reducing PM2.5 compared with the
usual care. It offers huge potential to reduce children’s’ tobacco-related harm by reducing exposure to SHS in the
home. The intervention is considered cost-effective if the decision maker is willing to pay £131 per additional 10μg/
m3 of PM2.5 reduction.
Trial registration: The Smoke Free Homes trial was registered with isrctn.com on 29 January 2013 with the
identifier ISRCTN81701383.
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Background
The harmful health effects of second-hand smoke (SHS),
also known as environmental tobacco smoke, on chil-
dren are well established [1, 2]. SHS exposure in chil-
dren is associated with higher risks of various diseases,
including asthma and wheeze [3], respiratory tract infec-
tions [4], middle ear disease [5], and even sudden infant
death syndrome [2]. The home is the main source of ex-
posure to SHS for children, particularly for young chil-
dren [6]. It is estimated that around 2 million children
are regularly exposed to SHS in the home in the UK [7].
As smoking prevalence is generally higher among care-
givers from socio-economically disadvantaged groups
[8], children from those households face higher exposure
to SHS and increased risk of developing SHS-related dis-
eases [9], which can lead to future health inequalities
through intergenerational perpetuation of tobacco de-
pendence and harm [10]. In the UK, SHS smoke in chil-
dren accounts for 165,000 new episodes of diseases, at
an estimated cost of about £23.3 million each year [2].
The long-term costs of treating smoking-caused diseases
for smokers who take up smoking as a consequence of
exposure to SHS has been estimated at £5.7million per
year, plus an additional annual £5.6 million in lost prod-
uctivity [2]. All these costs are potentially avoidable [2].
In addition to improved child health, reducing air pollu-
tion in the home will also benefit other family members.
Smoking cessation programmes are one of the most
cost-effective healthcare interventions available in the
UK [11–13]. The majority of smoking cessation inter-
ventions are focused on people who are motivated to
quit; less attention has been paid to those unwilling to
quit. This population, although unwilling to quit, may be
amenable to stop smoking within the home, reducing
the adverse effects on their children through SHS expos-
ure [14]. Despite the rapidly declining smoking preva-
lence in the UK, it is important to engage smokers from
disadvantaged groups and smokers unwilling to quit,
who have yet to respond to existing stimuli to quit [15].
A meta-analysis by Rosen et al. [16] evaluated seven
studies (six in the US and one in Scotland) aimed at re-
ducing SHS exposure. The results suggested that inter-
ventions aimed at reducing SHS exposure, with the
primary outcome as air pollution, were effective but lim-
ited. However, the cost-effectiveness of these interven-
tions was unclear since no analysis of cost-effectiveness
was conducted and no costs of intervention reported.
In this study, we report a cost-effectiveness analysis
(CEA) conducted in the context of a randomised con-
trolled trial (RCT) comparing a complex intervention
with usual care in reducing children’s SHS exposure in
the home [17]. The intervention consisted of both
pharmacological and behavioural support as well as a
personalised indoor air quality feedback. Our objectives
were to compare the costs associated with the complex
intervention strategies and the usual care, estimate the
effectiveness measured using PM2.5 levels, consumption
of cigarettes in the home, quit attempts and quit rates
and assess the cost-effectiveness of the complex inter-
vention compared with the usual care.
Methods
The smoke free homes trial
The trial for which the economic evaluation was con-
ducted was the Smoke Free Homes Trial (Trial registra-
tion: ISRCTN81701383), as reported in detail elsewhere
[17]. In brief, the trial was an open-label, parallel, RCT
based in deprived communities in Nottingham City and
County in England. Caregivers aged 18 and over, with a
child aged under five living in their household, reported
smoking tobacco inside their home and were not willing
to quit were recruited and randomised to receive either
the complex intervention or usual care. Participants
were recruited from 81 English ‘Sure Start’ Children’s
Centres across Nottinghamshire. A researcher and a
smoke-free homes advisor (SFHA) collected data during
home visits at baseline, seven and 12 weeks.
The complex intervention had several components, in-
cluding behavioural support from a SFHA on how to
create a SFH, feedback on the air quality measured in
the home, and nicotine replacement therapy (NRT) for
temporary abstinence or for reducing number of ciga-
rettes smoked in the home. Participants in the control
group received the usual care: a ‘SFH resource pack’ de-
veloped by the local Stop Smoking Service. Full details
of the study design and intervention have been described
in a companion paper presenting the clinical results of
the Smoke Free Homes trial [17]. This paper presents a
CEA carried out alongside the Smoke Free Homes Trial
to assess the value for money of the intervention.
Resource use
A micro-costing exercise was conducted following the
methods of technology appraisal recommended by the
National Institute for Health and Care Excellence
(NICE) [18]. The main costing component for the alter-
native strategies was the costs of inputs for the interven-
tions. No wider health care resource use was collected
and all trial-related research costs were excluded. Costs
for the intervention group were based on three compo-
nents: (1) up to four one-hour sessions of behavioural
support in the home from a SFHA and a minimum of
two proactive phone calls or SMS support; (2) NRT and
(3) feedback on the air quality (PM2.5) of the main living
area at baseline, seven and 12 weeks, measured using
the Sidepak Aerosol Monitor AM510 (TSI Instruments
Ltd., High Wycombe, UK) with the Trakpro software
already installed. Intervention cost for the usual care
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group was based on one face-to-face home visit and a
resource pack provided by Nottingham Smoke-free
homes. Intervention costs, therefore, included the staff
cost of the SFHAs along with the relevant travel and
telephone expenses, the cost of NRT and the air
monitors.
The household cost for contact with the SFHAs was
calculated from the treatment log, which recorded the
number of visits per household and the length of ap-
pointment for baseline, 7 weeks and 12 weeks. Where
an appointment time was not given, it was calculated
using the estimates of 10 min for graphical feedback and
10 min for behavioural support. For the intervention
group, the 24-h visit was estimated at 20 min and the
week three visit at 10 min. The advisor wage rate was
calculated from the mean of a band 5 and 6 smoking ad-
visor wage [19–21]. Travel time and distance from the
hospital were recorded in the treatment log. A return
trip was calculated based on the mileage, travel time and
advisor wage rate.
Within the treatment log telephone calls were re-
corded at 10 min per call. Before each visit an additional
courtesy call was made to the caregiver. NRT dispensed
per person was recorded within the treatment log and
costed according to the quantity given per household.
The cost of the air monitor was calculated for 1 year
of its 10 life-years (estimated by the manufacturer) and
then a cost per use was derived by dividing the annual
cost by the number of uses, based on the assumption
that the device could be used every other day. Included
in the annual cost were the yearly calibration and other
fixed costs such as the flow meter. Graphical feedback
was costed as 10 min of the appointment time with the
associated printing costs.
Valuation of costs
All resource use was valued in monetary terms, and unit
costs were reported in pounds sterling for the financial
year 2013/14. All costs were inflated to 2013/14 prices
levels where necessary, using the Hospital and Commu-
nity Health Services pay and price inflation index [22].
The follow-up for the analysis was 12 weeks from ran-
domisation, so no discounting was needed. Table 1 re-
ports the unit costs used in order to cost the
intervention. For the support pack, Public Health Eng-
land provided information on the Smokefree Homes and
Table 1 Unit costs and their sources
Resource Unit cost Sources
Smoking advisor £31/h Smoking Cessation Services (NICE) [19]
Travel £0.45/mile Estimated from Smoke Free Homes trial
Telephone call £0.63/min Estimated from Smoke Free Homes trial
SMS £0.04/text Estimated from Smoke Free Homes trial
Air monitor £0.60/use Calculated using manufacturer’s lifetime estimates
Support pack £1.45/pack Public Health England (PHE) [23]
Medication (Quantity per pack)
1.00 mg Nicorette Mouth Spray QuickMist - Double Pack (26) £19.43 Estimated from Smoke Free Homes trial
1.00 mg Nicorette Mouth Spray QuickMist - Individual Pack (13) £12.05
2.00 mg Nicorette Lozenge Nicorette Cool (20) £4.25
2.00 mg Nicorette Chewing Gum (30) £3.41
2.00 mg Nicorette Chewing Gum Icy White (30) £3.58
2.00 mg Nicorette Chewing Gum Icy White (105) £10.25
4.00 mg Nicorette Chewing Gum Icy White (105) £12.05
15.00 mg Nicorette Inhalator Inhalator (4) £4.35
15.00 mg Nicorette Inhalator Inhalator (20) £15.40
10.00 mg Nicorette Inhalator (starter pack) (6) £4.68
10.00 mg Nicorette Inhalator (refill pack) (42) £15.39
1.50 mg Niquitin CQ Lozenge Mint Mini Lozenge (20) £3.34
1.50 mg Niquitin CQ Lozenge Mini Lozenge (60) £9.37
4.00 mg Niquitin CQ Lozenge Mint Mini Lozenge (20) £3.18
4.00 mg Niquitin CQ Lozenge Mini Lozenge (60) £9.37
21.00 mg Nicotinell TTS 30 Patch (7) £8.73
14.00 mg Nicotinell TTS 20 Patch (7) £8.24
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Cars kit, last distributed in 2012 and the unit cost of
£1.45 was given, which was defined as covering produc-
tion costs only (printing and postage but not fulfilment
costs) [23].
Outcome measures
The primary outcome measure of the trial was the dif-
ference in average 16–24 h PM2.5 between baseline and
12 weeks. Secondary outcome measures included num-
ber of quitters (those who self-reported they had “quit
smoking altogether” at 12 weeks), number of quit at-
tempts (lasting longer than 24-h) and difference in
cigarette consumption (cigarettes smoked per day in the
home) between baseline and 12 weeks.
Cost-effectiveness analysis
A CEA was undertaken to combine the costs of the trial
intervention with PM2.5 level and the number of quit-
ters. The primary analysis was conducted on an intent–
to-treat (ITT) basis, whereby all randomised households
were included and analysed in the groups to which they
were randomised. Following NICE guidelines, the ana-
lysis was conducted from the NHS/Personal Social Ser-
vices perspective (including only costs that fall within
the healthcare and social services system).
This article’s companion paper used statistical models
to adjust for baseline covariates; since there was little
difference between those adjusted and those unadjusted,
we utilised raw adjustments for our analysis [17]. This
allowed us to present all results in the original units
(PM2.5, quitters, quit attempts, consumption of ciga-
rettes), which was more meaningful for an economic
evaluation than log-transforming PM2.5. The results
may differ slightly from the main paper because our
multiple imputation model contained cost variables. The
incremental cost-effectiveness ratio (ICER), in terms of
cost per additional 10μg/m3 reduction in PM2.5, was cal-
culated using the mean difference in cost between two
trial groups divided by the mean difference in effective-
ness [24]. The ICER was calculated using 10μg/m3 reduc-
tion, as this change in PM2.5 is utilised by the World
Health Organisation (WHO) for mortality risk and there-
fore considered a meaningful reduction [25]. An add-
itional ICER was calculated for cost per additional quitter.
The ICER is calculated using the formula below; ∆ repre-
sents difference, E represents effects, C represents the cost
of the intervention, while subscripts ‘I’ and ‘UC’ refer to
intervention and usual care, respectively [24].
ICER ¼
ΔC
ΔE
¼
CI−CUC
EI−EUC
Missing data for outcomes (16% for PM2.5) costs (7%)
resulted from lost-to-follow-up were imputed using
Rubin’s multiple imputation (MI) method [24, 26, 27].
As the data were not normally distributed, we used a
non-parametric bootstrap re-sampling method to test
the sensitivity of calculated ICERs [28–31]. 5000 esti-
mates of mean costs and mean QALYs were generated
for each intervention group and the results were then
displayed graphically using a cost-effectiveness plane
(CEP) to depict the uncertainty surrounding the mean
estimates. To assess the uncertainty surrounding the
ICER, bootstrapped 95% confidence intervals (CIs) were
generated.
In addition to the primary analysis based on the mul-
tiple imputed dataset, a sensitivity analysis was under-
taken to repeat the CEA using the 172 out of 204
households who had complete data for the primary out-
come and the 188 households who had complete data
for number of quitters. All analyses were conducted with
Stata version 14.0 and Excel (version 2013). Statistical
significance was accepted at P < 0.05 in each of the
analyses.
Results
A total number of 205 households were recruited to the
trial, but one withdrew from the intervention group,
resulting in 204 households (102 in each group) included
in the analysis. The majority of primary carers recruited to
the trial were female, with just 9% male; the mean age was
28, and 94% were white-British. Full details of trial partici-
pants and clinical outcomes are given elsewhere [17].
Table 2 presents a breakdown of the mean cost per
household for each element of the intervention. The
intervention group had a greater mean total intervention
cost than the usual care group (£328 (SD = £151) com-
pared to £45 (SD = £20)). The biggest drivers in this dif-
ference were the use of NRT, travel cost and staff time
also categorised as feedback time. Greater travel cost
was attributable to the extra visits required for the inter-
vention group, since the air monitor drop off/picks ups
and the week seven and week 12 follow ups were not in-
cluded in the costing of the usual care group, as these
were considered research costs only (maximum number
of visits costed for the intervention group was seven
compared to one for the usual care group).
Table 3 reports the base-case results with a decrease
of 22.1μg/m3 in average 16–24 h PM2.5 in the interven-
tion group, compared to just 0.5μg/m3 for the usual care
group (this is also presented in Table 3 by 10μg/m3 de-
crease, as was used for the ICER). This translated into a
41% mean reduction in the average 16–24-h average
PM2.5 between baseline and 12 weeks for the interven-
tion group, compared with a 1% mean reduction in the
usual care group. The quit rate was higher in the
intervention group versus the usual care group (8.0%
compared to 4.3%, p-value = 0.2614), but did not
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reach statistical significance in either analysis. Table 4
shows the intervention group experienced a mean re-
duction of 11 (SD = 10.7) cigarettes smoked in the
home per day compared with the usual care’s reduc-
tion of 4 (SD = 10.8) fewer cigarettes smoked
(p-value< 0.001). The quit attempt rate was signifi-
cantly higher in the intervention group (29.4% com-
pared to 8.6%, p-value< 0.001).
Tables 3 and 4 report the results of the complete
case analysis, although there was little variation. The
results only differed slightly between the base-case
analysis and the complete case analysis with the aver-
age 16–24 h PM2.5 results generally better for the
intervention group in the base-case.
The primary outcome, average 16 to 24-h PM2.5,
was selected for the CEA along with quitters. Table 3
presents the ICERs which combine the differential
costs of the two groups with the differential outcome
measures. The intervention group was more costly
than the usual care group, but had a greater decrease
in the PM2.5 level. This resulted in an ICER of £131
(bootstrapped 95% CI: £72–£467) per additional
10μg/m3 reduction of 16 to 24-h PM2.5. Analyses of
the quitters resulted in an ICER of £71 (−£57 to
£309) per additional quitter. The uncertainty sur-
rounding this ICER was reflected by the bootstrapped
CIs for both analyses. The complete case analysis
showed very similar results.
The bootstrapping results of the 5000 re-samples
for each outcome were plotted on a CEP (Fig. 1),
visually displaying any uncertainty surrounding the
mean differences in costs and benefits between the
intervention and usual care groups. Figure 1ashows
this uncertainty for the primary outcome (PM2.5 dif-
ference). The majority of the plots fall in the
south-east quadrant, this indicates although the inter-
vention is always more costly, it is more likely to be
effective at reducing PM2.5 levels, compared with
usual care. The quit rate is more uncertain as shown
by some of the plots falling in the south-east region
of the CEP (Fig. 1b) therefore there is a lack of evi-
dence to show the intervention was more effective at
helping people to quit. This is unsurprising, as this
was not the main aim of the trial.
Table 2 Mean total cost per household
Intervention (SD) (n = 102) Usual Care (SD) (n = 102) Difference (95% CI)
Staff £29 (£8) £11 (£3) £18 (£16 to £19)
Feedback £15 (£2.70) – £15 (£14.65 to £15.70)
Telephone £10 (£4) £0.10 (£0) £10 (£8.80 to £10.40)
Travel £216 (£143) £32 (£20) £184 (£156 to £213)
NRT £56 (£47) – £56 (£47 to £65)
Air monitor £1.68 (£0.32) – £1.68 (£1.62 to £1.74)
Support pack – £1.45 (£0) £1.45 (£1.45 to £1.45)
Total £328 (£151) £45 (£20) £283* (£254 to £313)
*Statistically significant (p-value< 0.001)
Table 3 Results of PM2.5and quit rate
Base-case analysis (with imputed data) Complete case analysis
Intervention Usual Care Difference (95% CI) P-
value
Intervention Usual care Difference (95% CI) P-
value
No. of households n = 102 n = 102 n = 204 n = 90 n = 82 n = 172
Cost (SD) £328 (£151) £45 (£20) £283 (£254 to £313) <
0.001
£331 (£149) £46 (£21) £285 (£252 to £318) <
0.001
Reduction in PM2.5 (ug/m
3) (SD) 22.1 (65.2) 0.5 (52.0) 21.6 (5.4 to 37.9) 0.0096 24.0 (58.9) 0.9 (52.4) 23.2(6.3 to 40.0) 0.007
Reduction in PM2.5 (10μg/m
3)
(SD)
2.21 (6.52) 0.05 (5.20) 2.16 (0.54 to 3.79) 0.0096 2.40 (5.89) 0.09 (5.24) 2.32 (0.63 to 4.0) 0.007
ICER (bootstrapped 95% CI) £131 (£72 to £467) £121 (£70 to £471)
No. of households n = 102 n = 102 n = 204 n = 95 n = 93 n = 188
Cost (SD) £328 (£151) £45 (£20) £283 (£254 to £313) <
0.001
£331 (£148) £44 (£21) £286 (£256 to £317) <
0.001
Quit rate (%)(SD) 8.0%
(27.0%)
4.3%
(19.6%)
3.7% (−2.8% to
10.2%)
0.2614 8.4%
(27.9%)
4.3%
(20.4%)
4.1% (−2.9% to
11.2%)
0.248
ICER (bootstrapped 95% CI) £71 (−£57 to £309) £72 (−£22 to £313)
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Discussion
To our knowledge, the present study is the first full
economic evaluation alongside an RCT to assess the
cost-effectiveness of a complex intervention designed
to reduce children’s exposure to SHS in the home.
The study has shown the complex intervention sig-
nificantly reduced SHS exposure in the home among
families in which parents had expressed no interest in
quitting smoking previously. Decision makers must be
willing to pay £131(bootstrapped 95% CI: £72–£467)
per additional 10μg/m3 reduction of PM2.5 in order to
reduce SHS in the home and limit harm to children.
It was presented per additional 10μg/m as this was
seen as a meaningful reduction and is used by WHO
when presenting mortality risk [25]. The results re-
vealed the intervention was more costly (mean cost:
£328 (SD = £151) vs £45 (SD = £20)) than usual care,
but produced better outcomes. Total mean costs were
£283 (95% CI: £254 to £313) higher in the interven-
tion group, this was mostly attributable to the cost of
travel with a mean difference of £184 (95% CI: £156
to £213) and the cost of NRT with a mean difference
of £56 (95% CI: £47 to £65). Based on WHO recom-
mendations, the safe level of PM2.5is < 25 μg/m
3 (24-h
mean), however children are recognised as particularly
vulnerable and there is no threshold below which ad-
verse health effects do not occur [25, 32]. Neither the
usual care nor intervention group met the WHO
threshold at 12 weeks (usual care = 47 μg/m3, inter-
vention = 32 μg/m3), but the intervention group did
experience an overall reduction of 41% from baseline
to 12 weeks.
The strength of the economic analysis has been im-
pacted by a few limitations of the study. Firstly, wider
health care resource use beyond the trial interventions
was not collected and this plays an important role in the
drive behind reducing SHS exposure. This cost dimen-
sion would have strengthened the economic analysis and
brought it more in line with NICE guidelines. Secondly,
the trial follow-up period was only 12 weeks, and it may
not be long enough to capture the full impact of the
intervention. Further research with longer-term
follow-up is needed to explore any potential long-term
benefits from the intervention.
This longer follow-up would also allow the use of the
EQ-5D and the subsequent calculation of Quality Ad-
justed Life-Years (QALYs), a generic health measure
[33–35]. QALYs can be used and easily compared across
interventions with a willingness to pay thresholds range
of £20,000 to £30,000 per additional QALY gained to de-
cide cost-effectiveness [18]. However, QALYs can be in-
sensitive to disease-specific conditions, in particular
those concerning mental health [36]. Thirdly, no defini-
tive conclusion about cost-effectiveness can be made
due to the absence of decision-making thresholds for
any of the outcomes collected alongside the trial.
These limitations aside, this trial targeted a socio-eco-
nomically disadvantaged population that has been
neglected within the literature. Previous research showed
great success with sophisticated methods for interven-
tions aimed at smokers who are serious about and will-
ing to quit [37, 38]. Despite the rapidly declining
smoking prevalence, it is important to engage with
smokers who have not yet responded to existing stimuli
to quit [15]. New and innovative approaches are needed
to target those who are not willing to quit, but may be
willing to reduce consumption in the home, thereby lim-
iting the impact of SHS on children. Our results showed
a reduced number of cigarettes being smoked inside the
home and lower PM2.5 level, indicating some success in
the trial aims. Although not statistically significant, this
intervention group had a 3.7% higher quit rate than
usual care, suggesting even those who are seemingly not
willing to quit are still able to and should not be ignored,
but this result should be taken with caution due to the
high level of uncertainty. The results showed a higher
number of quit attempts in the intervention group
(20.8% higher quit attempt rate). Chaiton et al. [39]
Table 4 Results of consumption of cigarettes in the home and quit attempts
Base-case analysis (with imputed data) Complete case analysis
Intervention Usual
Care
Difference (95%
CI)
P-
value
Intervention Usual
care
Difference (95%
CI)
P-
value
No. of households n = 102 n = 102 n = 204 n = 95 n = 93 n = 188
Cost (SD) £328 (£151) £45 (£20) £283 (£254 to
£313)
<
0.001
£330(£148) £44(£21) £286 (£256 to
£317)
<
0.001
Reduction of consumption in the home (no. of
cigarettes per day) (SD)
11 (10.7) 4 (10.8) 7 (9.8 to 3.9 to
9.8)
<
0.001
11 (10.8) 4 (10.5) 7.5 (4.4 to 10.6) <
0.001
No. of households n = 102 n = 102 n = 204 n = 93 n = 93 n = 186
Cost (SD) £328 (£151) £45 (£20) £283 (£254 to
£313)
<
0.001
£331 (£149) £44 (£21) £286 (£256 to
£318))
<
0.001
Quit attempt rate (%)(SD) 29.4%
(43.6%)
8.6%
(27.1%)
20.7% (10.8% to
30.8%)
<
0.001
29% (45.6%) 8.6%
(28.2%)
20.4% (7.3% to
32.0%)
<
0.001
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argue when taking into account those smokers who are
less willing to quit, it may take 30 or more quit attempts
before being successful. Therefore, these increased quit
attempts may indicate a likelihood of longer term
success.
More high quality research such as larger RCTs with
longer follow-up periods, generic health outcome mea-
sures and collection of wider healthcare resource use is
needed to explore the impact of complex interventions
on reducing children’s SHS exposure. Furthermore, stud-
ies exploring interventions that help those who are not
willing to quit smoking are needed. These interventions
may have short term objectives of reduced consumption,
but with the potential of long term success of quitting.
Conclusions
This trial targeted a socio-economically disadvantaged
population that has been neglected within the litera-
ture. The complex intervention was more costly but
more effective in reducing PM2.5 compared with the
usual care. It offers huge potential to reduce chil-
dren’s’ tobacco-related harm by reducing exposure to
secondhand tobacco smoke in the home. The inter-
vention is considered cost-effective if the decision
maker is willing to pay £131 per additional 10μg/m3
of PM2.5 reduction.
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